• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Infectious Disease

Typhoid vaccine Phase 3 trial in Nepal

byNiki WintersandDeepti Shroff, DMD, MS
January 1, 2020
in Infectious Disease, Pediatrics, Public Health
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In Nepal, the typhoid conjugate vaccine has proven to be very effective in protecting against typhoid fever.

2. The typhoid antibody titers more than quadrupled in the participants that received the typhoid conjugate vaccine.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Typhoid fever is a bacterial infection caused by Salmonella that leads to a high fever, weakness, stomach pain, and rash. It is a major public health problem in the summer months among children in South Asian countries, such as India, Bangladesh, Pakistan, and Nepal. The oral vaccine has proven to be less effective in children than adults for multiple reasons. This randomized controlled trial was phase 3 of the typhoid conjugate vaccine to determine efficacy in Nepal, a typhoid fever endemic area. Children in this study received either the typhoid vaccine or control vaccine and were followed for 6 months. In participants who received the typhoid vaccine, typhoid fever occurred less commonly, and antibody titers were higher than the control group. Within a week of vaccination, the most common side effects were pain at the injection site, fever, vomiting, and diarrhea. The typhoid vaccine group reported less adverse events within 1 month and 6 months of the vaccine, when compared to the control group. No deaths related to the vaccine were reported.

Follow-up of these participants is on-going and is important to determine long-term efficacy and safety of the vaccine. If this vaccine proves to be effective long-term, it will be able to help prevent typhoid fever among children and travelers to high-risk countries.

Click to read the study in the NEJM (New England Journal of Medicine)

RELATED REPORTS

Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine

Typhoid conjugate vaccine shows promising long-term efficacy in children

Relevant Reading: The Severe Typhoid Fever in Africa Program Highlights the Need for Broad Deployment of Typhoid Conjugate Vaccines

In-Depth [randomized controlled trial]: This phase 3, double-blind, randomized controlled trial included 20,019 participants from Nepal to examine the effectiveness of the typhoid conjugate vaccine in an endemic area. Participants received the vaccine between 2017 and 2018, with follow-up into 2019. Children between the ages of 9 months and 16 years in good health were included in the study. Children were randomly assigned to groups based on age – either the conjugated typhoid vaccine group or meningococcal conjugate vaccine (control). Participants were followed to determine if the vaccine prevented typhoid fever, developed immunogenicity, and reported adverse events. Confirmed typhoid fever occurred in 0.07% of the typhoid vaccine group, compared to 0.38% of the control group. The protective efficacy of the typhoid vaccine was 81.6% (95% CI, 58.8 to 91.8; P<0.001). Vaccine efficacy was 85.1% in participants who had at least 3 days of fever (95% CI; 49.7 to 95.6). 28 days after receiving the vaccine, antibody titers more than quadrupled in 99.1% of the typhoid vaccine group versus 2.1% in the control group. Within 7 days of vaccination, the most common side effects were pain at vaccination site, feeling generally unwell, having a fever, vomiting and diarrhea, and decreased appetite. Within 28 days of the vaccination, 7 adverse events were reported in the typhoid vaccine group versus 10 in the control group. Within 6 months of the vaccination, 61 adverse events were reported in the typhoid vaccine group versus 71 in the control group. The most common adverse events reported were pneumonia and pyrexia.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: antibody titersNepalSouth asiatyphoid vaccine
Previous Post

Association of prehospital plasma transfusion with survival in trauma patients with hemorrhagic shock when transport times are longer than 20 minutes

Next Post

Ultra-processed foods linked to increased risk of type 2 diabetes

RelatedReports

Vaccination collage: a smiling woman with a round plaster on her upper arm beside an open cool box of capped vaccine vials
Infectious Disease

Next-generation yellow fever vaccine shows comparable efficacy to standard vaccine

April 8, 2026
Childhood vaccination collage: a globe ringed by a teal ribbon before a shield, a capped syringe and a round bandage
Infectious Disease

Typhoid conjugate vaccine shows promising long-term efficacy in children

March 26, 2024
Initial data on the viability of SARS-CoV-2 in aerosol and on surfaces
Chronic Disease

Higher SARS-CoV-2 antibody titers in patients hospitalized with MIS-C

November 17, 2020
#VisualAbstract: Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal
StudyGraphics

#VisualAbstract: Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal

January 16, 2020
Next Post

Ultra-processed foods linked to increased risk of type 2 diabetes

#VisualAbstract: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

#VisualAbstract: Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent

MIV-711 effective in reducing bone and cartilage manifestations for patients with osteoarthritis

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • PROT-001 was generally safe and well tolerated in a phase 1 study of healthy volunteers with AL amyloidosis
  • 2MM: AI Roundup- PTSD Prediction, Gait as a Biomarker, Faster Cardiac MRI, and Perinatal Mental Health Chatbots [November 12th, 2026]
  • Large genetic association study identifies additional Alzheimer disease risk loci and candidate pathways
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.